GlassScriptPhysician profile
Reuben S Henderson
NPI 1851463228
$3,529.19
in general payments reported to CMS, 2019-2025
31 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $503 · 2021: $615 · 2022: $553 · 2023: $432 · 2024: $359 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $775.64 | 2019-2025 | Xtampza |
| Abbvie INC. | $638.75 | 2021-2025 | |
| Pfizer INC. | $208.76 | 2019-2025 | |
| Orexo US, INC. | $203.83 | 2019-2025 | Zubsolv |
| Teva Pharmaceuticals USA, INC. | $165.09 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.95 | 2019-2023 | Relistor |
| Amgen INC. | $159.14 | 2019-2022 | |
| Allergan, INC. | $149.85 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $138.05 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.70 | 2022 | |
| Medtronic, INC. | $90.43 | 2023-2024 | Activos 10 Bone Cement, Accurian |
| Supernus Pharmaceuticals, INC. | $85.54 | 2019-2020 | |
| Redhill Biopharma INC. | $72.34 | 2020-2022 | |
| Braeburn INC. | $60.23 | 2024-2025 | Brixadi |
| Indivior INC. | $58.87 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $54.04 | 2021 | |
| Avanir Pharmaceuticals, INC. | $51.33 | 2021 | |
| Lilly USA, LLC | $48.60 | 2019-2020 | |
| Averitas Pharma INC. | $36.17 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $31.10 | 2020-2021 | |
| Eisai INC. | $30.96 | 2021 | |
| Biodelivery Sciences International, INC. | $30.31 | 2021 | |
| Daiichi Sankyo INC. | $30.17 | 2019 | |
| Hikma Pharmaceuticals USA | $25.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.03 | 2023 | Ztlido |
| Antares Pharma, INC. | $16.42 | 2024 | Xyosted |
| Ibsa Pharma INC. | $15.42 | 2021 | |
| Forte Bio-Pharma LLC | $13.92 | 2024 | Prolate, Nalocet |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2022 | |
| Assertio Therapeutics, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.